<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908580</url>
  </required_header>
  <id_info>
    <org_study_id>MT_PRT_ST02</org_study_id>
    <nct_id>NCT03908580</nct_id>
  </id_info>
  <brief_title>MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity</brief_title>
  <official_title>A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is &quot;A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial
      to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb
      Spasticity&quot;.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2013</start_date>
  <completion_date type="Actual">March 31, 2015</completion_date>
  <primary_completion_date type="Actual">October 31, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in muscle tone determined by MAS (Modified Ashworth Scale) of wrist flexor</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of wrist flexor in subjects with post stroke upper limb spasticity at week 4 after administration compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle tone determined by MAS (Modified Ashworth Scale) of elbow flexor and finger flexor</measure>
    <time_frame>4 weeks, 16 weeks, and 4 weeks after re-visit</time_frame>
    <description>Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of elbow flexor and finger flexor at week 4 and 16 after administration compared to baseline, and at 4 weeks after re-administration compared to the time of re-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in muscle tone determined by MAS (Modified Ashworth Scale) of wrist flexor</measure>
    <time_frame>16 weeks, and 4 weeks after re-visit</time_frame>
    <description>Change in muscle tone determined by MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) of wrist flexor at week 16 after administration compared to baseline, and at 4 weeks after re-administration compared to the time of re-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effective rate of wrist flexor, elbow flexor, and finger flexor</measure>
    <time_frame>4 weeks, 16 weeks, and 4 weeks after re-visit</time_frame>
    <description>The effective rate of wrist flexor, elbow flexor, and finger flexor at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit, defining the muscle with MAS (Modified Ashworth Scale: Measures resistance during passive soft-tissue stretching; score 0 to 4, 4 being most difficult passive movement) score of ≥1 among the wrist flexor, elbow flexor, and finger flexor muscles as responders when the MAS is reduced by 1 score compared to baseline (week 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS (Disability Assessment Scale) score</measure>
    <time_frame>4 weeks, 16 weeks, and 4 weeks after re-visit</time_frame>
    <description>Change in score of goal assessment section in DAS (Disability Assessment Scale: Measures disability associated with upper limb spasticity in patients; score 0 to 3, 3 being the most severe disability) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL (SF-36v2; Quality of Life) score</measure>
    <time_frame>4 weeks, 16 weeks, and 4 weeks after re-visit</time_frame>
    <description>Change in score of Short Form 36 ver.2 (SF-36v2; Quality of Life, QOL: a questionnaire with 36 questions regarding general health change affecting patient's quality of life; score from 1 up to 5, from minimum to high impact on quality of life) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's or caregiver's global assessment</measure>
    <time_frame>4 weeks, 16 weeks, and 4 weeks after re-visit</time_frame>
    <description>Subject's or caregiver's global assessment (rating from -3 to +3 on the overall treatment effect, with +3 being very satisfied with treatment) at week 4 and 16 compared to baseline and at week 4 after re-administration compared to re-visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs) to assess safety of investigational product.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Safety of IP assessed by the number of partiicipants with adverse events determined by MedDra ver 16.0 from enrollment to the end of study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Spasticity, Muscle</condition>
  <arm_group>
    <arm_group_label>Meditoxin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A was intramuscularly injected up to 360U and up to 4 sites, depending on the muscle size.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meditoxin</intervention_name>
    <description>Meditoxin® (Botulinum toxin type A) was injected up to 360 U.</description>
    <arm_group_label>Meditoxin®</arm_group_label>
    <other_name>Neuronox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female over 20 years.

          2. Subjects that was diagnosed with stroke at least 1 month before participating in the
             clinical trial.

          3. Subjects with MAS score of ≥2 for local muscle spasticity of wrist flexor.

        Exclusion Criteria:

          1. Subjects with generalized neuromuscular junction disorder (ex: myasthenia gravis,
             Lambert-Eaton syndrome, amyotrophic lateral sclerosis, etc.).

          2. Subjects with fixed joint, muscle contracture, or atrophy in the treatment area.

          3. Subjects with botulinum toxin treatment within 3 months before administration of the
             investigational product.

          4. Known immunization or hypersensitivity to any botulinum toxin preparations.

          5. Subjects who have recieved the following treatments within 4 weeks from screening:
             Muscle relaxants, Benzodiazepines, Aminoglycosides, Other antibiotics,
             Anticholinergics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 7, 2019</last_update_submitted>
  <last_update_submitted_qc>April 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

